TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES

摘要

Administration of sPLA2 inhibitors in combination with statins has been found to reduce major adverse cardiac events (MACEs), inflammatory biomarker levels, and LDL-C levels in subjects who have recently experienced an index ACS event to a significantly greater degree than statins alone. These results were unexpected given previous results showing that statins alone are insufficient to satisfactorily reduce MACEs and inflammation in this high-risk population. Therefore, provided herein are methods of treating MACEs, treating ACS, inhibiting inflammation, and lowering cholesterol levels in a subject who has previously experienced an ACS event by administering one or more sPLA2 inhibitors alone or in combination with one or more statins.